Xiaoban Xin, Ph.D.
Dr. Xiaoban Xin assists companies and research institutes with preparing and prosecuting patent applications, patent portfolio management, strategic patent counseling, and due diligence.
Xiaoban has specific experience working with clients in the fields of biotechnology, including gene editing (e.g., CRISPR technology), next generation sequencing, immunotherapy, cell therapy, biologics, small molecules, stem cells, genetically modified animals, and pharmaceutical formulations.
Xiaoban also has extensive experience in the fields of medical device, chemical engineering and materials, energy and cleantech, mechanical engineering, and health IT.
Prior to practicing law, Xiaoban was a Technology Transfer Fellow at the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institute of Health (NIH), where he managed IP portfolios and drafted technology transfer agreements.
Xiaoban received his Ph.D. from The University of Texas Health Science Center and post-doc training at the Johns Hopkins University School of Medicine, where he studied molecular mechanisms underlying diabetes and retinopathy. His research has been published in a number of professional journals.
Xiaoban is fluent in Mandarin Chinese.
Areas of Concentration
Publications & Presentations
Xin X, “Patent Eligibility of 3D-Printed Organs,” AIPLA Quarterly Journal, Vol. 44, No. 1, 2016
Tan Y, Xin X, Coffey FJ, Wiest DL, Dong LQ, Testa JR. Appl1 and Appl2 are Expendable for Mouse Development But Are Essential for HGF-Induced Akt Activation and Migration in Mouse Embryonic Fibroblasts. J Cell Physiol. (2016) 231(5): 1142-50.
Babapoor-Farrokhran S, Jee K, Puchner B, Hassan SJ, Xin X et al. Angiopoietin-like 4 is a potent angiogenic factor and a novel therapeutic target for patients with proliferative diabetic retinopathy. Proc Natl Acad Sci USA. (2015) 112(23):E3030-9.
Ryu J, Galan AK, Xin X et al. APPL1 potentiates insulin sensitivity by facilitating the binding of IRS1/2 to the insulin receptor. Cell Rep. (2014) 7(4): 1127-38.
Krispel C, Rodrigues M, Xin X, Sodhi A. Ranibizumab in diabetic macular edema. World J Diabetes. (2013) 4(6): 310-8.
Xin X, Rodrigues M, Umapathi M et al. Up-regulation of Angiopoietin-like 4 Promotes Vascular Permeability in Ischemic Retinal Disease. Proc. Nad. Acad. Sci USA. (2013) 110(36): E3425-34.
Rodrigues M, Xin X et al. VEGF Secreted by Hypoxic Miiller Cells Induces MMP-2 Expression and Activity in Endothelial Cells to Promote Retinal Neovascularization in Proliferative Diabetic Retinopathy. Diabetes. (2013) 62(II): 3863-73.
Xin X, Zhou L, Reyes CM, Liu F, Dong LQ. APPL1 mediates adiponectin-stimulated p38 MAPK activation by scaffolding TAKI-MKK3-p38 MAPK pathway. Am. J. Physiol. Endocrinol. Metab. (2011) 300(1): E103-10.
Wang C, Xin X, Xiang R, Ramos FJ, Liu M, Lee HJ, Chen H, Mao X, Kikani CK, Liu F, Dong LQ. Yin-Yang regulation of adiponectin signalling by APPL isoforms in muscle cells. Biol. Chem. (2009) 284(46): 31608-31615.
Wang C, Liu M, Riojas RA, Xin X, Gao Z, Zeng R, Wu J, Dong LQ, Liu F. PKC(theta)-dependent phosphorylation of PDK1 at SER504 and SER532 constributes to palmitate-induced insulin resistance. J. Biol. Chem. (2009) 284(4): 2038-2044.
Liu M, Zhou L, Xu A, Lams KS, Wetzel MD, Xiang R, Zhang J, Xin X, Dong LQ, Liu F. A disulfide-bond A oxidoreductase-like protein (DsbA-L) regulates adiponectin multimerization. Proc. Nad. Acad. Sci. USA. (2008) 105(47): 18302-18307.
Chen T, Cui J, Liang Y, Xin X, Owen Young D, Chen C, Shen P. Identification of human liver mitochondrial aldehyde dehydrogenase as a potential target for microcystin-LR. Toxicology. (2006) 220(1): 71-80.
Zhao S, Shen P, Zhou Y, Wei Y, Xin X, Hua Z. Selecting peptide ligands and microcystin-LR from phage displayed random libraries. Environ. Int. (2005) 31(4): 535-541.